Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received focal therapy as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study.

Focal ablation of prostate cancer using different modalities. These modalities include:

* Cryoablation or Cryotherapy
* Irreversible Electroporation - Nanoknife
* High Intensity Frequency Ultrasound - FocalOne
* Transurethral Ultrasound Ablation - TULSA - PRO

Focal Therapy

Juan Javier-DesLoges, MD

This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.

This observational study will serve to collect data from medical record and review questionnaires before and after focal ablation of prostate tissue. All enrolled subjects will have already undergone or scheduled to receive the focal therapy as part of their prostate cancer treatment.

Urine and Blood samples will be collected on patients for bio banking and future analysis.

Focal Therapy for Localized Prostate Cancer

A Prospective Registry and Longitudinal Study of Patients Undergoing Focal Therapy for Localized Prostate Cancer

The following definitions will be used for evaluation of oncological response:

Complete response: Ablation of prostate tissue in targeted biopsy cores at 12 months.

Incomplete response: Residual disease at 12 months compared to baseline in target biopsy cores or systematic biopsy cores.

Assess impact on erections after ablation. The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) questionnaire will be used to evaluate sexual health quality-of-life symptoms for participants pre- and post-ablation.

Patients will receive a score between 0 and 12, 0 being low with a better outcome and 12 being high with a worse outcome.

Assess impact on continence after ablation. The Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) questionnaire will be used to evaluate urinary health quality-of-life symptoms for participants pre- and post-ablation.

Patients will receive a score between 0 and 12, 0 being low with a better outcome and 12 being high with a worse outcome.

Assess long-term recurrence risk after ablation

University of California, San Diego

Assistant Professor of Urology

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection

Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery

High Intensity Focused Ultrasound (HIFU) to the Breast Cancer

Gurdeep S Mannu, MRCSEd DPhil

High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.

In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated

High Intensity Focused Ultrasound (HIFU) treatment to breast cancer

The HIFUB Study (HIFU in Breast Cancer)

Study of High Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer

Volume of tumour ablation on histological examination of the surgically excised specimen expressed as a percentage of pretreatment tumour volume on MRI scan.

Volume of tumour ablation on histological examination of the surgically excised specimen and volume of tumour ablation on post-treatment MRI expressed as a percentages of pretreatment tumour volume on MRI scan.

Using the Common Toxicity Criteria for Adverse Events (CTCAC) Grading Guideline (which scores any occurring adverse events with grades between 1 to 5, where higher grades indicate worse outcomes)

Using 1 to 1 qualitative interviews with participants.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Focal Therapy for Localized Prostate Cancer	NCT06270043	Prostate Cancer	Focal Therapy	18 Years -	University of California, San Diego
The HIFUB Study (HIFU in Breast Cancer)	NCT05350059	Breast Cancer	High Intensity ...	18 Years -	University of Oxford
Focal Therapy for Localized Prostate Cancer	NCT06270043	Prostate Cancer	Focal Therapy	18 Years -	University of California, San Diego
The HIFUB Study (HIFU in Breast Cancer)	NCT05350059	Breast Cancer	High Intensity ...	18 Years -	University of Oxford

Spots Global Cancer Trial Database for high intensity frequency ultrasound